The concept of CR2-fH providing optimal longer-term protection by self-limited complement activation is further supported by findings that high-dose, but not low-dose, C3aR antagonism impaired post-stroke SVZ neurogenesis in the subacute phase [14, 24]. The gene discussed is C3AR1; the disease is stroke disorder.